Exploring New Therapeutic Treatments for Dementia: Promising Alzheimer's Products Aim to Combat Memory Loss

Alessandro De Luca* and Giovanni Esposito

Department of Clinical and Experimental Medicine, University of Molise, Italy

Abstract

Dementia, particularly Alzheimer's disease, remains a significant challenge in the medical field due to the lack of a definitive cure. Researchers are continuously seeking innovative therapeutic treatments to address the cognitive decline associated with these conditions. Recently, several new Alzheimer's products have shown promise in mitigating memory loss and improving the quality of life for patients. These advancements in therapeutic approaches include pharmaceutical developments, lifestyle interventions, and novel technologies aimed at slowing disease progression and enhancing cognitive function. This paper reviews the latest findings and explores the potential of these emerging therapies to transform the landscape of dementia treatment.

*Corresponding author: Alessandro De Luca, Department of Clinical and Experimental Medicine, University of Molise, Italy, E-mail: Alessandro.De@Luca.it

Clinical trials and outcomes

Lifestyle Interventions

Dietary approaches

Physical activity and exercise

Cognitive training and rehabilitation

Novel Technologies

Neurostimulation techniques

Digital health tools

Biomarker development and early detection

Emerging Alzheimer's Products

Innovative therapies in development

Citation: De Luca A (2024) Exploring New Therapeutic Treatments for Dementia: Promising Alzheimer's Products Aim to Combat Memory Loss. J Dement 8: 214.

Page 3 of 5

[illegible paragraph text]

Case studies of promising products

[illegible paragraph text]

Potential for personalized medicine

[illegible paragraph text]

Methodology

Literature Review

[illegible paragraph text]

Data collection

[illegible paragraph text]

Inclusion and exclusion criteria

[illegible paragraph text]

Citation: De Luca A (2024) Exploring New Therapeutic Treatments for Dementia: Promising Alzheimer's Products Aim to Combat Memory Loss. J Dement 8: 214.

Page 4 of 5

Clinical trials and outcomes

Physical activity and exercise

Cognitive training and rehabilitation

Novel Technologies

Neurostimulation techniques

Biomarker development and early detection

Emerging Alzheimer's Products

Innovative therapies in development

Case studies of promising products

Potential for personalized medicine

Conclusion

[illegible]

Acknowledgment

[illegible]

Conflict of Interest

[illegible]

References

1. Robine J-M, Paccaud F (2005) Nonagenarians and centenarians in Switzerland, 1860–2001: a demographic analysis. J Epidemiol Community Health 59: 31–37.
2. Ankri J, Poupard M (2003) Prevalence and incidence of dementia among the very old. Review of the literature. Rev Epidemiol Sante Publique 51: 349–360.
3. Wilkinson TJ, Sainsbury R (1998) The association between mortality, morbidity and age in New Zealand's oldest old. Int J Aging Hum Dev 46: 333–343.
4. Miles TP, Bernard MA (1992) Morbidity, disability, and health status of black American elderly: a new look at the oldest-old. J Am Geriatr Soc 40: 1047–1054.
5. Gueresi P, Troiano L, Minicuci N, Bonafé M, Pini G, et al. (2003) The MALVA (MAntova LongeVA) study: an investigation on people 98 years of age and over in a province of Northern Italy. Exp Gerontol 38: 1189–1197.
6. Nybo H, Petersen HC, Gaist D, Jeune B, Andersen K, et al. (2003) Predictors of mortality in 2,249 nonagenarians—the Danish 1905-Cohort Survey. J Am Geriatr Soc 51: 1365–1373.
7. Silver MH, Newell K, Brady C, Hedley-White ET, Perls TT (2002) Distinguishing between neurodegenerative disease and disease-free aging: correlating neuropsychological evaluations and neuropathological studies in centenarians. Psychosom Med 64: 493–501.
8. Stek ML, Gussekloo J, Beekman ATF, Van Tilburg W, Westendorp RGJ (2004) Prevalence, correlates and recognition of depression in the oldest old: the Leiden 85-plus study. J Affect Disord 78: 193–200.
9. von Heideken Wågert P, Rönnmark B, Rosendahl E, Lundin-Olsson L, M C Gustavsson J, et al. (2005) Morale in the oldest old: the Umeå 85+ study. Age Ageing 34: 249–255.
10. Von Strauss E, Fratiglioni L, Viitanen M, Forsell Y, Winblad B (2000) Morbidity and comorbidity in relation to functional status: a community-based study of the oldest old (90+ years). J Am Geriatr Soc 48: 1462–1469.
11. Andersen HR, Jeune B, Nybo H, Nielsen JB, Andersen-Ranberg K, et al. (1998) Low activity of superoxide dismutase and high activity of glutathione reductase in erythrocytes from centenarians. Age Ageing 27: 643–648.